CD276 and neoplasm: At the same time, other study also found that CD276 was up-regulated in tumor cells of lung cancer patients treated with trametinib, which can achieve better therapeutic effect after combined B7-H3 × T cell bispecific antibody treatment, and this also proves that CD276 is a potential therapeutic target for lung cancer.